Department of Cardiosciences, Division of Cardiology, A. O. San Camillo-Forlanini, 00152 Rome, Italy.
Department of Medicine, Unit of Cardiovascular Science, Campus Bio-Medico University, 00128 Rome, Italy.
Rev Cardiovasc Med. 2021 Sep 24;22(3):731-740. doi: 10.31083/j.rcm2203080.
Recurrent myocardial infarction (re-MI) is a common event following acute coronary syndrome (ACS), especially during the first year. According to epidemiological studies, patients who experience re-MI are at higher risk of all-cause cardiovascular events and mortality. The cornerstones of re-MI prevention include complete functional coronary revascularization, effective dual antiplatelet therapy and secondary prevention strategies. Notwithstanding this, some controversy still exists on the definition and management of re-MI, and no dedicated studies have been designed or conducted so far in this setting. We here provide an overview of epidemiological and prognostic data on ACS patients experiencing re-MI, along with current available treatment and preventive options.
复发性心肌梗死（re-MI）是急性冠状动脉综合征（ACS）后的常见事件，尤其是在第一年。根据流行病学研究，经历 re-MI 的患者发生全因心血管事件和死亡的风险更高。re-MI 预防的基石包括完全功能性冠状动脉血运重建、有效的双联抗血小板治疗和二级预防策略。尽管如此，关于 re-MI 的定义和管理仍存在一些争议，迄今为止，在这一领域尚未设计或进行专门的研究。我们在此概述了经历 re-MI 的 ACS 患者的流行病学和预后数据，以及目前可用的治疗和预防选择。
